Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 5/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | YES1 | P07947 | 1/20 | 0.31 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.31 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.31 |
| ▸ | LTK | P29376 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | MST1R | Q04912 | 1/20 | 0.31 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL534877 | 1.00 | MET (0.33) | METKDRAURKAABL1LCK | |
| SCHEMBL534865 | 0.93 | MET (0.34) | METKDRAURKAABL1LCK | |
| SCHEMBL534864 | 0.93 | MET (0.34) | METKDRAURKAABL1LCK | |
| SCHEMBL534531 | 0.89 | MET (0.33) | METKDRAURKAABL1LCK | |
| SCHEMBL534532 | 0.89 | MET (0.33) | METKDRAURKAABL1LCK | |
| SCHEMBL534769 | 0.88 | MAPT (0.34) | METKDRAURKAABL1LCK | |
| SCHEMBL534770 | 0.88 | MAPT (0.34) | METKDRAURKAABL1LCK | |
| SCHEMBL534573 | 0.88 | MET (0.34) | METKDRAURKAABL1LCK | |
| SCHEMBL534675 | 0.88 | MET (0.34) | METKDRAURKAABL1LCK | |
| SCHEMBL534572 | 0.88 | MET (0.34) | METKDRAURKAABL1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507509-B2 | Saturated and insaturated bi- or tricyclic aryloxyacetamine derivatives and their use as fungicides | SYNGENTA CROP PROTECTION LLC (US) | 2013-08-13 | — | — | US | disclosed |
| EP-2185518-B1 | Aryloxyacetamide derivatives and their use as fungicides | SYNGENTA PARTICIPATIONS AG (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20100298356-A1 | SATURATED AND INSATURATED BI- OR TRICYCLIC ARYLOXYACETAMINE DERIVATIVES AND THEIR USE AS FUNGICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298356-A1 | SATURATED AND INSATURATED BI- OR TRICYCLIC ARYLOXYACETAMINE DERIVATIVES AND THEIR USE AS FUNGICIDES | CYP1A2, CYP1B1, CYP1A1 | MET 780/4885KDR 3582/4885AURKA 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.